Quinolones

被引:18
作者
Alós, JI [1 ]
机构
[1] Hosp Mostoles, Microbiol Serv, Madrid 28935, Spain
来源
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA | 2003年 / 21卷 / 05期
关键词
quinolones; fluoroquinolones; antimicrobial agents; review;
D O I
10.1157/13046545
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Ouinolones act by inhibiting enzymes (topoisomerases), which are indispensable to DNA synthesis. Their bactericidal activity is concentration-dependent. Their spectrum has become broader, especially since the introduction of a fluorine atom at position 6 (fluoroquinolones). They are used as the treatment of choice or as alternative therapy in a wide variety of infections, both in the hospital and non-hospital setting. Depending on the compound, they are used in urinary tract infections, sexually transmitted diseases, chronic osteomyelitis, respiratory tract infections, and severe systemic infections, among others. The upsurge and extent of quinolone resistance has limited the use of these agents in some cases and in future may determine their use in others. There are strategies to minimize the spread of resistance. Quinolones are safe and well tolerated. The most frequent adverse effects are gastrointestinal and those affecting the central nervous system.
引用
收藏
页码:261 / 268
页数:8
相关论文
共 59 条
  • [31] High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA
    Mazzariol, A
    Tokue, Y
    Kanegawa, TM
    Cornaglia, G
    Nikaido, H
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (12) : 3441 - 3443
  • [32] Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA
    Muñoz-Bellido, JL
    Manzanares, MAA
    Andrés, JAM
    Zufiaurre, MNG
    Ortiz, G
    Hernández, MS
    García-Rodríguez, JA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) : 354 - 356
  • [33] Emergence of macrolide resistance during treatment of pneumococcal pneumonia
    Musher, DM
    Dowell, ME
    Shortridge, VD
    Flamm, RK
    Jorgensen, JH
    Le Magueres, P
    Krause, KL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (08) : 630 - 631
  • [34] Classification of fluoroquinolones
    Naber, KG
    Adam, D
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 1998, 10 (04) : 255 - 257
  • [35] Guidelines for the management of adults with community-acquired pneumonia - Diagnosis, assessment of severity, antimicrobial therapy, and prevention
    Niederman, MS
    Mandell, LA
    Anzueto, A
    Bass, JB
    Broughton, WA
    Campbell, GD
    Dean, N
    File, T
    Fine, MJ
    Gross, PA
    Martinez, F
    Marrie, TJ
    Plouffe, JF
    Ramirez, J
    Sarosi, GA
    Torres, A
    Wilson, R
    Yu, VL
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 163 (07) : 1730 - 1754
  • [36] Oteo J, 1999, Clin Microbiol Infect, V5, P654, DOI 10.1111/j.1469-0691.1999.tb00427.x
  • [37] Clinical use of the fluoroquinolones
    Owens, RC
    Ambrose, PG
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 2000, 84 (06) : 1447 - +
  • [38] Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients - A randomized, double-blind trial
    Peacock, JE
    Herrington, DA
    Wade, JC
    Lazarus, HM
    Reed, MD
    Sinclair, JW
    Haverstock, DC
    Kowalsky, SF
    Hurd, DD
    Cushing, DA
    Harman, CP
    Donowitz, GR
    [J]. ANNALS OF INTERNAL MEDICINE, 2002, 137 (02) : 77 - 86
  • [39] EVALUATION OF INTRAVENOUS CIPROFLOXACIN IN PATIENTS WITH NOSOCOMIAL LOWER RESPIRATORY-TRACT INFECTIONS - IMPACT OF PLASMA-CONCENTRATIONS, ORGANISM, MINIMUM INHIBITORY CONCENTRATION, AND CLINICAL CONDITION ON BACTERIAL ERADICATION
    PELOQUIN, CA
    CUMBO, TJ
    NIX, DE
    SANDS, MF
    SCHENTAG, JJ
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1989, 149 (10) : 2269 - 2273
  • [40] PEREZTRALLERO E, 1990, EUR J CLIN MICROBIOL, V9, P905